NCT05933499View on ClinicalTrials.gov

Effect of Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults with Obesity

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Obesity
Interventions
DRUG

IV bimagrumab

IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)

DRUG

IV placebo

IV placebo (administered at 0, 4, 16, 28, and 40 weeks)

DRUG

Semaglutide

Semaglutide 2.4mg SQ qweek

DIETARY_SUPPLEMENT

Calcium/Vitamin D

Elemental calcium 1200 mg + vitamin D3 800 IU PO daily

BEHAVIORAL

Lifestyle and nutrition counseling

Lifestyle and nutrition counseling consistent with current guidelines for weight management

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER